Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

More EU Notified Bodies Bite The Dust

Executive Summary

The number of notified bodies operating under the EU's current medical device directives continue to decline, and that trend is expected to persist with the new regulations entering into force. Here's a look at country-by-country trends in notified bodies operating under the three current medtech EU directives.

You may also be interested in...



Combining EU Notified Body MDR/IVDR Assessments: Can It Speed Things Along?

As the date that EU notified bodies can submit for designation under the new regulations rapidly approaches, can EU designating authorities audit notified bodies against the MDR and IVDR at the same time to improve efficiency? And can notified bodies audit against the legacy directives alongside the regulations to minimize worst-case logjams?

EU MDR Set To Rack Up Costs For Industry, German Medtechs Say

Prepare for notified body bottlenecks and skyrocketing clinical evaluation costs for medical devices as you comply with the EU Medical Device Regulation (MDR): that's what German medtech industry delegates were told at a legal and regulatory symposium last week.

IVD UK Spring Meeting: The Costly But Necessary Route To IVDR Compliance

Second of two articles covering discussion at the spring 2017 meeting of the British In Vitro Diagnostics Association: Not all will survive unscathed as the EU IVD Regulation becomes an operational reality.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT104879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel